| Typicality: | 0.484 |
| Saliency: | 0.345 |
| in the united states | 9 | location |
| by the fda | 3 | other |
| in 1967 | 2 | temporal |
| drug → be approved for → clinical use | 27 |
| drug → be approved for → new indication | 5 |
| drug → be approved for → the indication | 4 |
| drug → be approved for → indication | 4 |
| negative | neutral | positive |
| 0.115 | 0.607 | 0.278 |
| Raw frequency | 40 |
| Normalized frequency | 0.345 |
| Modifier score | 0.767 |
| Perplexity | 36.620 |